Kodiak Sciences Inc.

NasdaqGM:KOD Stock Report

Market Cap: US$280.3m

Kodiak Sciences Past Earnings Performance

Past criteria checks 0/6

Kodiak Sciences's earnings have been declining at an average annual rate of -26.9%, while the Biotechs industry saw earnings growing at 19.3% annually.

Key information

-26.9%

Earnings growth rate

-22.8%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth raten/a
Return on equity-92.2%
Net Marginn/a
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

Aug 02
We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

Apr 17
We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

Dec 29
We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate

Sep 09
We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate

Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Deliver On Growth Plans?

May 26
Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Deliver On Growth Plans?

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

Jan 04
We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

Here's Why We're Watching Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation

Sep 25
Here's Why We're Watching Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation

GreenWood Investors - Kodiak Sciences: The Busted Biotech World

Aug 25

Kodiak Sciences FQ1 2022 Earnings Preview

Aug 07

Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Invest In Growth?

May 18
Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Invest In Growth?

Kodiak Sciences: Potential For Comeback After Trial Setback

May 17

Kodiak Sciences: KSI-301 Disappoints

Feb 25

Highlighting Kodiak Sciences: A Great Buy Here Ahead Of Phase 3 Wet AMD Data For KSI-301 This Quarter

Feb 15

We're Hopeful That Kodiak Sciences (NASDAQ:KOD) Will Use Its Cash Wisely

Jan 24
We're Hopeful That Kodiak Sciences (NASDAQ:KOD) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation

Oct 11
Here's Why We're Not Too Worried About Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation

Kodiak Sciences: Our Current Take On This Mid-Cap Biotech Company

Jul 19

Kodiak Sciences EPS in-line

May 10

Kodiak Sciences hits the capital raise button; shares dip after hours

Nov 16

Kodiak Sciences EPS misses by $0.12

Nov 09

Revenue & Expenses Breakdown

How Kodiak Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:KOD Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-19867145
31 Mar 240-23369180
31 Dec 230-26071206
30 Sep 230-27172216
30 Jun 230-29872241
31 Mar 230-30972248
31 Dec 220-33474268
30 Sep 220-35773287
30 Jun 220-34767282
31 Mar 220-31259253
31 Dec 210-26750217
30 Sep 210-22042179
30 Jun 210-18938152
31 Mar 210-15933128
31 Dec 200-13329107
30 Sep 200-1022283
30 Jun 200-781864
31 Mar 200-641552
31 Dec 190-471238
30 Sep 190-461132
30 Jun 190-441026
31 Mar 190-41821
31 Dec 180-41819
30 Sep 180-38621
30 Jun 180-32519
31 Mar 180-31521
31 Dec 170-28322

Quality Earnings: KOD is currently unprofitable.

Growing Profit Margin: KOD is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: KOD is unprofitable, and losses have increased over the past 5 years at a rate of 26.9% per year.

Accelerating Growth: Unable to compare KOD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: KOD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: KOD has a negative Return on Equity (-92.16%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies